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To the Editor:
Bruton tyrosine kinase (BTK) inhibitors have greatly
improved the spectrum of treatment options in mantle cell
lymphoma (MCL) [1–4]. Acalabrutinib is a highly selective,
orally administered, and potent BTK inhibitor with limited
off-target activity [5]. Acalabrutinib was approved in 2017
by the US Food and Drug Administration for the treatment
of relapsed/refractory MCL based on clinical data from the
open-label, multicenter, phase 2 ACE-LY-004 study of
acalabrutinib 100 mg twice daily [1]. Here, we present
updated results from the ACE-LY-004 study after a median
26-month follow-up.
Eligibility criteria and study design were published pre-
viously (Supplementary methods) [1]. Analysis of minimal
residual disease (MRD) was conducted after complete
response (CR) or partial response (PR) was achieved
using the quantitative ClonoSEQ next-generation sequen-
cing (5 × 10−6) assay (Adpative Biotechnologies, Seattle,
WA, USA) in consenting patients with available paired
archival tumor and whole blood samples. Data are updated
as of February 12, 2018.
A total of 124 patients across 40 centers were enrolled
and treated; demographic data were previously reported
(Supplementary Table 1) [1]. Cytomorphological variants
included classical (n= 89 [72%]), blastoid/pleomorphic
(n= 26 [21%]), or other (n= 9 [7%]). Ki-67 data were
available for 96 patients (77%); 32/96 patients (33%) had a
Ki-67 proliferation index ≥50%. The mean Ki-67 pro-
liferation index for blastoid/pleomorphic patients (n= 21)
was 55.8% (SD: 22.3) vs 34.5% (SD: 22.6) in patients with
classical MCL (n= 68); seven patients with Ki-67 data
were in the other variant category.
The median follow-up was 26 months (range, 0.3–35.1).
Forty percent of patients remain on treatment, and 61%
remain in follow-up for survival (Supplementary Table 2).
After discontinuing acalabrutinib, six patients received
allogeneic stem-cell transplants at a median of 19 days after
discontinuation (range, 1–95).
Response to acalabrutinib was maintained similar to the
original report [1], with an overall response rate (ORR) of
81% and 43% CR rate (Supplementary Table 3). The
median duration of response (DOR) was 26 months (95%
CI, 17.5, not reached), with an estimated 24-month DOR of
52.4% (95% CI, 41.5, 62.2; Fig. 1a). The median
progression-free survival (PFS) was 20 months (95% CI,
16.5, 27.7), and the estimated 24-month PFS rate was
49.0% (95% CI, 39.6, 57.8; Fig. 1b). The median overall
survival (OS) was not reached; the estimated 24-month OS
rate was 72.4% (95% CI, 63.5, 79.5; Fig. 1c). ORR was
consistent across patients with refractory disease and those
with blastoid/pleomorphic MCL, despite those patients
having a higher mean Ki-67 index ≥50%, suggesting that
some patients with poorer prognosis may also beneﬁt from
acalabrutinib (Supplementary Table 4). Prolonged median
DOR, median PFS, and 24-month OS rates, however, were
observed in patients with low/intermediate Mantle Cell
Lymphoma International Prognostic Index scores, classical
MCL, and Ki-67 index <50% (Supplementary Figs. 1–4).
Twenty-nine patients (23%) had evaluable samples
available for MRD analysis (Supplementary Fig. 5). Seven
of 29 patients (24%) had MRD-negative (5 × 10−6) disease
in peripheral blood after achieving a response (CR or PR).
All seven patients with MRD-negative disease were in CR.
Seventeen of 29 patients had a second blood sample
approximately 6 months after the ﬁrst, including ﬁve of the
seven MRD-negative patients. Sustained MRD negativity
was observed in four of the ﬁve patients. An additional
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Fig. 1 Kaplan–Meier curves for time-to-event endpoints. Curves
shown are duration of response in responding patients (a), progression-
free survival (b), and overall survival (c). DOR duration of response,
NR not reached, OS overall survival, PFS progression-free survival
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patient with CR who was MRD positive in the ﬁrst sample
became MRD negative in the second sample. Therefore, a
total of 8/29 patients (28%) achieved MRD negativity at
any time on acalabrutinib monotherapy. Despite limited
samples, these results demonstrate that continued use of
acalabrutinib can lead to undetectable MRD in patients with
CR. Since most patients with MRD data are still on treat-
ment (27/29), relationships between MRD negativity and
durability of reponse cannot be made at this time.
The adverse event AE proﬁle was largely consistent with
earlier reporting [1], with no new safety signals after an
additional year of follow-up. The most frequent AEs
(≥20%) were primarily grade 1/2 and included headache
(38%), diarrhea (36%), fatigue (28%), cough (22%), and
myalgia (21%; Supplementary Table 5). The most common
events, headache and diarrhea, were mostly grade 1/2,
occurred early in treatment, and were manageable. Head-
ache events occurred primarily within the ﬁrst month of
treatment and most diarrhea events occurred in the ﬁrst
6 months of treatment (Table 1 and Supplementary
Table 6). The percentage of patients experiencing grade ≥3
AEs or serious AEs was similar to that previously reported
(Supplementary Table 7), indicating that sustained use of
acalabrutinib may not lead to cumulative toxicities [1].
Thirteen patients (10%) had cardiac events, including four
grade 3/4 events (3%). As previously reported, one patient
each had acute coronary syndrome (considered treatment
related by investigator), acute myocardial infarction (not
treatment related), and cardiorespiratory arrest (not treatment
related) [1]; one grade 3 event (coronary artery disease [not
treatment related]) occurred during this long-term follow-up.
Consistent with the previous report [1], there were no new
atrial ﬁbrillation events (Table 1). One patient with a his-
tory of paroxysmal atrial ﬁbrillation was initially assessed
as experiencing an AE of atrial ﬁbrillation, but the AE was
reconsidered by the investigator since the condition was
preexisting and did not worsen on study drug. No new
hypertension events occurred with long-term follow-up. As
previously reported, four patients had hypertension events
(3%), with one grade 3 event [1]. Bleeding events of any
grade occurred in 33% of patients, most commonly con-
tusion (13%) and petechiae (9%), and markedly decreased
over time (Table 1). All bleeding events were grade 1/2
except for three grade 3 events (gastrointestinal hemor-
rhage, hematuria, hematoma). Two of the three major
hemorrhage events occurred after the previous report,
though the rate of major hemorrhage events (2%) remains
the lowest reported for a BTK inhibitor with ≥2 years of
follow-up [1, 6]. Anticoagulant use was reported in 57
patients (46%) while on study, but there was no reported
use of concurrent anticoagulants in the patients with the
three grade 3 hemorrhage events during the events. Con-
sistent with previous reporting, most infections were grade
1/2, were considered unrelated to study treatment, and were
not serious. Here, we also show that the frequencies of any
grade, grade ≥3, and serious infections decreased over time
(Table 1). Grade 3/4 infections occurred in 15% of patients,
most commonly pneumonia (n= 7 [6%]); no grade 5
infections occurred. As previously reported, there was one
case of cytomegalovirus viremia and one case of Pneu-
mocystis jiroveci pneumonia (both grade 2), with no
Aspergillus infections [1]. Mean immunoglobulin levels
Table 1 Incidence of select adverse events by 6-month intervals
Adverse event, n (%) 1–6 months
(n= 124)
7–12 months
(n= 99)
13–18 months
(n= 74)
19–24 months
(n= 65)
>24 months
(n= 55)
Headache, any grade 42 (34) 2 (2) 0 0 0
Grade ≥3 2 (2) 0 0 0 0
SAE 1 (1) 0 0 0 0
Diarrhea, any grade 31 (25) 8 (8) 3 (4) 5 (8) 5 (9)
Grade ≥3 3 (2) 1 (1) 0 0 0
SAE 0 0 1 (1) 0 0
Infection, any grade 51 (41) 20 (20) 17 (23) 11 (17) 6 (11)
Grade ≥3 11 (9) 4 (4) 2 (3) 2 (3) 1 (2)
SAE 8 (6) 4 (4) 2 (3) 2 (3) 1 (2)
Bleeding events, any grade 31 (25) 14 (14) 5 (7) 4 (6) 0
Major hemorrhagea 1 (1) 0 0 2 (3) 0
Atrial ﬁbrillation, any gradeb 0 0 0 0 0
Rash, any grade 10 (8) 5 (5) 2 (3) 1 (2) 0
Grade ≥3 1 (1) 0 1 (1) 1 (2) 0
SAE 0 0 0 0 0
SAE serious adverse event.
aDeﬁned as grade ≥3, SAE and/or any grade or seriousness of central nervous system hemorrhage.
bThere was one event of atrial ﬁbrillation in a subject with a history of paroxysmal atrial ﬁbrillation (removed by investigator as this preexisting
condition did not worsen on study drug).
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did not change much over time (Supplementary Fig. 6).
Rashes were infrequent and mostly grade 1/2. Second
primary cancers occurred in ten patients (8%; Supple-
mentary Table 8).
Treatment discontinuation was primarily due to pro-
gressive disease (n= 54 [44%]) and AEs (n= 10 [8%]).
Ten patients discontinued treatment due to AEs; each AE
occurred in one patient. AEs leading to discontinuation
were aortic stenosis, diffuse large B-cell lymphoma, blood
blister and petechiae (both in one patient with grade 3 acute
coronary syndrome treated with clopidogrel), dyspnea and
leukostasis syndrome (both in one patient), noncardiac chest
pain, pulmonary ﬁbrosis, rash, thrombocytopenia, non-
small cell lung cancer, and pulmonary embolism. AEs led to
dose delays (missed ≥1 dose) in 39 patients (31%) and dose
modiﬁcation (≥1 dose at 100 mg once daily) in two patients
(2%; Supplementary Table 9).
There were 43 deaths (35%), most commonly from
progressive disease (n= 29 [23%]). Six patients (5%) died
due to AEs, including bilateral pulmonary embolism, aortic
stenosis (in a patient with a history of aortic stenosis), mye-
lodysplastic syndrome, pneumonia, suicide, and non-small
cell lung cancer. Two patients (2%) died of unknown causes
≥198 days after the last dose, and one patient (1%) died due to
multiorgan failure 176 days after the last dose. Five patients
(4%) died of “other” causes (secondary acute myeloid leu-
kemia ≥277 days after last dose [n= 2]; intestinal obstruction
63 days after last dose [n= 1]; lung cancer 728 days after last
dose [n= 1]; and graft-vs-host disease 275 days after the
last dose [n= 1; patient received an allogeneic stem-cell
transplant 95 days after last dose]).
Extended follow-up of a median 26 months revealed
continued efﬁcacy and favorable safety with single-agent
acalabrutinib in relapsed/refractory MCL. Differences
between patient populations and staging criteria in the
current study and the single-arm study of the other approved
BTK inhibitor ibrutinib preclude comparison between stu-
dies, regardless of similar follow-up time (27 months in the
ibrutinib study) [6]. Nonetheless, the response rates and
median DOR based on the Lugano classiﬁcation in this
study are the highest reported among all approved single-
agent therapies for the treatment of relapsed/refractory
MCL. Moreover, four patients with PR converted to CR
with longer follow-up indicating improvement of response
(similar to ibrutinib [2, 6]), and most responders maintained
a response for over 2 years. Nearly half of all patients
remain progression free after 2 years of treatment, with few
discontinuations due to AEs (8%). AEs considered asso-
ciated with BTK inhibition continued to occur at relatively
low rates or not at all, including no new onset of atrial
ﬁbrillation. Taken together, these ﬁndings further support
the favorable beneﬁt-risk proﬁle of acalabrutinib mono-
therapy in relapsed/refractory MCL.
Acknowledgements This study was sponsored by Acerta Pharma, a
member of the AstraZeneca Group. We thank the patients who
participated in this trial and their families and caregivers; the
investigators and coordinators at each study site; and the Acerta
Pharma study team, including Soﬁa Wong. Medical writing assis-
tance was provided by Stephanie Morgan of Team9Science and
funded by Acerta Pharma.
Author contributions RI, SR, and MW designed the study. DN and PP
performed the literature search. OC, AD, JDo, JDu, RE, GD, AG,
MDD, APK, TL, SLG, FM, LO, CP, DN, PP, TR, BS, SDS, MW, and
PLZ collected the data. GD veriﬁed the data. EJ, APK, DN, PP, MY,
MMF, and MW analyzed the data. AD, RI, MDD, APK, TL, FM, LO,
CP, DN, PP, SR, and SDS interpreted the data. MY and MMF pro-
duced the ﬁgures. MW wrote the ﬁrst draft. All authors contributed to
the writing and reviewing of manuscript content and approved the ﬁnal
version of the manuscript.
Compliance with ethical standards
Conﬂict of interest MW is a consultant for AstraZeneca, Janssen, and
MoreHealth, has received honoraria from Acerta Pharma, Celgene,
Dava Oncology, Janssen, and Pharmacyclics, has received research
funding from Acerta Pharma, AstraZeneca, Celgene, Janssen, Kite
Pharma, Juno, Novartis, and Pharmacyclics, and is a member of the
Board of Directors or advisory committees for Celgene and Janssen.
SR is a consultant for, a member of the Board of Directors or advisory
committees for, and has received honoraria from AstraZeneca,
Celgene, Celltrion, Gilead, Janssen, Kite, and Roche, has received
research funding from Janssen, and participates in a speakers’ bureau
for Celgene. PLZ has received honoraria from BMS, Celgene,
Celltrion, Gilead, Janssen, MSD, Roche, and Servier, and participates
in a speakers’ bureau for AstraZeneca, BMS, Gilead, Janssen, MSD,
Servier, and Verastem. AG is a consultant for Acerta Pharma, Celgene,
Kite/Gilead, Pharmacyclics/J&J, and Takeda, has received honoraria
from Celgene, Pharmacyclics/J&J, and Takeda, is a member of the
Board of Directors or advisory committees for Acerta Pharma,
Celgene, COTA, Kite/Gilead, Pharmacyclics/J&J, and Takeda, has
received research funding from Acerta Pharma, Celgene, Genentech,
Kite/Gilead, Pharmacyclics/J&J, and Seattle Genetics, and participates
in a speakers bureau for Acerta Pharma, Celgene, Pharmacyclics/J&J,
and Takeda. OC is a consultant for Gilead, Janssen, Merck, MSD,
Roche, and Takeda, has received honoraria from Celgene, Gilead,
Janssen, Merck, MSD, Roche, and Takeda, and has received research
funding from Gilead and Roche. SDS is a consultant for Merck Sharpe
Dohme and Corp, and has received research funding from Acerta
Pharma, Genentech, Merck Sharpe Dohme and Corp, Pharmacyclics,
Portola, and Seattle Genetics. FM is a consultant for Celgene and
Gilead, is a member of the Board of Directors or advisory committees
for BMS, Celgene, Gilead, and Roche, and gives scientiﬁc lectures for
Janssen and Roche. CP is a consultant for Roche, participates in a
speakers’ bureau for Celgene, Janssen, and Roche, has received
research funding from Acerta Pharma, is a member of the Board of
Directors or advisory committees for BMS and Janssen. AD is a
consultant for Acerta Pharma, Celgene, Janssen, Karyopharma, Kite,
Roche, and Takeda, and has received research funding from Acerta
Pharma, Celgene, Gilead, GSK, Karyopharma, Pﬁzer, and Roche. BS
reports relationships with Amgen, Incyte, and Pharmacyclics that do
not exceed $5000, nor are relevant to this content. RE is a member of
the Ramsay Hospital Medical Advisory Committee. EJ is a consultant
for AstraZeneca, Merck, and Seattle Genetics. APK has received
honoraria from Abbie, Genentech, and Janssen, and research funding
from Abbie, Acerta/AstraZeneca, Genentech, and Janssen. LO is a
consultant for Janssen, Sanoﬁ, and Takeda, and has received honoraria
from Janssen. TR has received research funding from Acerta Pharma.
Letter 2765
DN, MY, and PP are employees of Acerta Pharma and have equity
ownership of Acerta and AstraZeneca. RI is an employee of, has
equity ownership of and patents at Acerta Pharma, and has equity
ownership of AstraZeneca. MMF is an employee of and has equity
ownership and patents at AstraZeneca. MDD is a consultant for
Janssen, Roche, Servier and Takeda, and gives scientiﬁc lectures
for Janssen, Servier, and Roche. GD, JD, JKD, SL, and TL declare
no competing interests.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD,
et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma
(ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet
2018;391:659–67.
2. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al.
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell
lymphoma. N Engl J Med 2013;369:507–16.
3. Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks
RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell
lymphoma. N Engl J Med 2018;378:1211–23.
4. Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny
M, et al. Ibrutinib versus temsirolimus in patients with relapsed or
refractory mantle-cell lymphoma: an international, randomised,
open-label, phase 3 study. Lancet 2016;387:770–8.
5. Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B,
et al. Acalabrutinib (ACP-196): a covalent Bruton Tyrosine kinase
inhibitor with a differentiated selectivity and in vivo potency pro-
ﬁle. J Pharm Exp Ther 2017;363:240–52.
6. Wang ML, Blum KA, Martin P, Goy A, Auer R, Kahl BS, et al.
Long-term follow-up of MCL patients treated with single-agent
ibrutinib: updated safety and efﬁcacy results. Blood 2015;
126:739–45.
2766 Letter
